CompletedNot Applicable

The mCRC Patients With pMMR/MSS or dMMR/MSI-H Status Received Palliative Chemotherapy Efficacy and Survival

China671 participantsStarted 2019-09-01

Plain-language summary

Deficient mismatch repair (dMMR) or microsatellite instability high (MSI-H) accounts for 4-5% in metastatic colorectal cancer (mCRC). The efficacy and survival of patients with dMMR/MSI-H status received palliative chemotherapy have not clear yet. In this study, the investigators observed the efficacy and survival of dMMR/MSI-H status mCRC patients received palliative first-line chemotherapy.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age ≥ 18 years old
✓. Histologically confirmed Metastatic colorectal adenocarcinoma;
✓. Immunohistochemistry confirmed mismatch repair status or polymerase chain reaction (pCR) / next-generation sequencing (NGS) confirmed microsatellite status
✓. Received palliative chemotherapy and have complete information of treatment

Exclusion criteria

✕. Patients have not tested for mismatch repair or microsatellite
✕. Patients have not received palliative chemotherapy or received palliative chemotherapy but treatment information incomplete

What they're measuring

Progression-Free Survival (PFS)

Timeframe: up to 24-36 months

Trial details

NCT IDNCT04482608

SponsorSun Yat-sen University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2020-04-01

View on ClinicalTrials.gov More Colorectal Cancer Metastatic trials